Legend Biotech Corporation - American Depositary Shares (LEGN)
38.10
+0.88 (2.36%)
Legend Biotech Corp is a biotechnology company focused on the development and commercialization of innovative cell therapies for the treatment of cancer and other serious diseases
The company leverages its proprietary technologies to create advanced cellular therapies, particularly in the realm of engineered T cell therapy, aiming to harness the body's immune system to target and eliminate malignant cells. Through rigorous research and clinical trials, Legend Biotech is committed to addressing unmet medical needs and enhancing patient outcomes in the field of oncology.
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by 45% compared to standard therapies.
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding in Legend By Molly Wen
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your portfolio?
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy compared to standard treatments. Safety data align with the approved label.
